


Almonertinib mesylate

Chemical Properties

CAS No. :	2134096-06-1
Formula:	C31H39N7O5S
Molecular Weight:	621.75
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Almonertinib mesylate is an irreversible inhibitor of EGFR tyrosine kinase with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib mesylate can be used in the non-small cell lung cancer studies.
Targets(IC50)	EGFR
In vitro	Almonertinib shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC50: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM)[1]. Additionally, HS-10296 could also inhibit other EGFR sensitive mutations, including G719X, del19, L858R and L861Q[2].

Solubility Information

Solubility	DMSO: 40 mg/mL (64.33 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.6084 mL	8.0418 mL	16.0836 mL
5 mM	0.3217 mL	1.6084 mL	3.2167 mL
10 mM	0.1608 mL	0.8042 mL	1.6084 mL
50 mM	0.0322 mL	0.1608 mL	0.3217 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Sullivan I, et al. Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line. *Front Med (Lausanne)*. 2017 Jan 18;3:76.

Wu SG, et al. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. *Mol Cancer*. 2018 Feb 19;17(1):38.

Yang JC, et al. Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial [published online ahead of print, 2020 Sep 9]. *J Thorac Oncol*. 2020;S1556-0864(20)30714-0.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481